2022 Lower Extremity Spasticity Epidemiology Report: Focus on US, Germany, Spain, Italy, France, UK & Japan 2019-2032 – ResearchAndMarkets.com | Business and finance

DUBLIN–(BUSINESS WIRE)–January 25, 2022–

The Lower Extremity Spasticity Epidemiology Division provides information on the historical and current patient base and projected trends for seven major countries. Epidemiological data on lower extremity spasticity are studied in all possible divisions to give a better understanding of the disease scenario in 7MM.

The Epidemiology of Lower Limb Spasticity segment covers epidemiological data in the United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom) and Japan from 2019 to 2032. It also helps to identify the causes of current and predicted trends by exploring numerous studies, survey reports and insights from key opinion leaders.

The calculated data is presented with relevant tables and graphs to give a clear view of the epidemiology at first glance.

  • Lower Limb Spasticity report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment regimens
  • The Lower Limb Spasticity Epidemiology Report and Model provides an overview of global lower limb spasticity trends across the top seven markets (7MM: US, France, Germany, Italy, Spain, UK & Japan)
  • The report provides an overview of the historical and forecast lower limb spasticity patient base in seven major markets spanning the US, EU5 (Germany, Spain, France, Italy, UK) and Japan.
  • The report helps recognize growth opportunities in 7MM for the patient population
  • Report assesses risk and burden of disease and highlights unmet needs of lower extremity spasticity
  • The report provides segmentation of lower limb spasticity epidemiology
  • 11-year predictions of the epidemiology of lower limb spasticity
  • 7MM cover
  • Prevalent and diagnosed cases of lower extremity spasticity
  • Cases of lower limb spasticity by mutation types
  • Cases of lower limb spasticity associated with clinical manifestations
  • Patient segmentation
  • Risk and burden of disease
  • Disease risk by segmentation
  • Factors favoring the growth of a specific patient population

2. Executive Summary of Lower Limb Spasticity

3. Spasticity of the lower limbs: background and overview of the disease

5. Epidemiology and patient population

5.1. Main epidemiological results

5.2. Assumptions and justification: 7MM

5.3. Epidemiological scenario: 7MM

5.3.1. Epidemiology scenario of lower limb spasticity in 7MM (2019-2032)

5.4. Epidemiology in the United States

5.4.1. US Lower Limb Spasticity Epidemiology Scenario (2019-2032)

5.5. Epidemiology by EU-5 country

5.5.1. Germany Epidemiology

5.5.1.1. Epidemiology scenario of lower limb spasticity in Germany (2019-2032)

5.5.2. France Epidemiology

5.5.2.1. Epidemiological scenario of lower limb spasticity in France (2019-2032)

5.5.3. Italy Epidemiology

5.5.3.1. Epidemiology scenario of lower limb spasticity in Italy (2019-2032)

5.5.4. Spain Epidemiology

5.5.4.1. Epidemiology scenario of lower limb spasticity in Spain (2019-2032)

5.5.5. United Kingdom Epidemiology

5.5.5.1. UK Lower Limb Spasticity Epidemiology Scenario (2019-2032)

5.6.1. Japan Lower Limb Spasticity Epidemiology Scenario (2019-2032)

6. Treatment Algorithm, Current Treatment and Medical Practices

6.1. Treatment and management of lower extremity spasticity

6.2. Lower limb spasticity treatment algorithm

Laura Wood, Senior Press Officer

For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright BusinessWire 2022.

PUBLISHED: 01/25/2022 11:42 AM / DISK: 01/25/2022 11:43 AM

Copyright BusinessWire 2022.